Search clinical trials for: Vidaza

Total 336 results

Zhujiang Hospital

Recruiting

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

Leukemia, Myeloid, Acute

China
LEO Pharma

Recruiting

Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight (ADJUST)

Psoriasis Vulgaris

Belgium, Italy, Spain, Germany, Czechia, Greece, United Kingdom, France, Hungary, Poland, Netherlands
Yale University

Completed

Window Trial 5-aza in HNSCC, T-tare

Head and Neck Squamous Cell Carcinoma

United States
Associazione Qol-one

Completed

Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients

Acute Myeloid Leukemia

Italy
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Completed

Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

Acute Myeloid Leukemia

United States
ConvaTec Inc.

Completed

Vitala 12 Hour Wear Test With Convex Products

End Colostomy

United States
Materia Medica Holding

Completed

Study on Efficacy and Safety of Divaza in Patients With Chronic Cerebral Ischemia and Cognitive Disorders (DIAMANT)

Chronic Cerebral Ischemia
New Mexico Cancer Care Alliance

Completed

A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies

Advanced Solid Tumor Malignancies

United States
University of Utah
Celgene Corporation

Completed

A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer (VA)

Advanced or Metastatic Solid Tumors | Advanced or Metastatic Breast Cancer

United States
Sun Yat-sen University

Recruiting

Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

China
Guangdong Provincial People's Hospital

Unknown

Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma

China
Nordic MDS Group

Unknown

The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

Sweden
Peking University
Peking University International Hospital; Hebei Medical University Fourth Hospital

Unknown

Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma

Experimental Tumor

China
Dong mei

Unknown

Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety

Adenocystic Carcinoma

China
University of Washington

Completed

Social Media for ART Adherence and Retention in Adolescents and Young Adults: the Vijana-SMART Study

Depression | Adherence, Medication | HIV-1-infection

Kenya
Materia Medica Holding

Completed

Clinical Trial of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis

Cerebral Atherosclerosis

Russian Federation
Washington University School of Medicine
Genzyme, a Sanofi Company

Completed

A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma

Relapsed Or Refractory Multiple Myeloma

United States
University of Illinois at Chicago

Recruiting

BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer (BRE-04)

Breast Cancer Female | Breast Cancer Invasive

United States
Seoul St. Mary's Hospital
Celgene Corporation

Unknown

5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

Korea, Republic of
Groupe Francophone des Myelodysplasies

Completed

Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

France
Celgene

Completed

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Leukemia, Myelomonocytic, Juvenile | Myelodysplastic Syndrome

Spain, Germany, Italy, United Kingdom, Belgium, France, Denmark, Netherlands, Sweden, Switzerland, Austria, Czechia, Ireland
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Ph II Study of Azacitidine in Myelofibrosis

Myelofibrosis

United States
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation (AGIR)

Recurrent IDH1/2 Mutated Glioma

France
Groupe Francophone des Myelodysplasies
Celgene

Completed

A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders

MDS | Systemic Autoimmune Diseases

France
Celgene

Completed

Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

China
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)

Leukemia | Myelodysplastic Syndrome

United States
Patrick Stiff

Recruiting

Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS

Myelodysplastic Syndrome MDS | Acute Myelogenous Leukemia AML

United States
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS

MDS

United States
Kansas City Veteran Affairs Medical Center

Unknown

Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy

Acute Myeloid Leukemia | Elderly

United States
Genentech, Inc.

Completed

A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy

Leukemia, Myeloid, Acute

United States, Canada
Celgene

Completed

AVIDA The Vidaza® (Azacitidine) Patient Registry (AVIDA)

Myelodysplastic Syndromes

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation

Completed

Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy

Leukemia

United States
National Taiwan University Hospital

Not yet recruiting

Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum

Acute Kidney Disease

Taiwan
Celgene

Completed

Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea

Myelodysplastic Syndrome

Korea, Republic of
S*BIO

Completed

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

Myelodysplastic Syndrome | Solid Tumors | Hematologic Malignancies

United States, Singapore
Helsinn Healthcare SA

Completed

Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Celgene

Completed

Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma (RACE)

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Leukemia, Myelomonocytic, Chronic

United States
Washington University School of Medicine

Completed

A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Technische Universität Dresden

Completed

Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza) (RELAZA2)

Myelodysplastic Syndrome | Acute Myelocytic Leukemia

Germany
Hutchison Medipharma Limited

Terminated

Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Celgene

Completed

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function (RENAL)

Multiple Myeloma | Non-Hodgkin's Lymphoma | AML | Solid Tumors | MDS | Hodgkin's Disease

United States
University of Chicago

Recruiting

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

Chronic Myeloid Leukemia | Myelofibroses

United States
Grupo Cooperativo de Estudio y Tratamiento de las...
Celgene Corporation; Germans Trias i Pujol Hospital; Hospital Son Llatzer

Unknown

Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT)

Myelodysplastic Syndromes

Spain
Heinrich-Heine University, Duesseldorf

Completed

Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Germany
Brian Jonas
Pharmacyclics LLC.

Completed

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Refractory Anemia With Excess Blasts in Transformation

United States
Hospices Civils de Lyon

Unknown

Action of the Vidaza on the Atrial Fibrillation (AVIFA)

Atrial Fibrillation | Acute Leukemia

France
Groupe Francophone des Myelodysplasies
Novartis

Completed

A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients (LDE255)

MDS

France
Swiss Group for Clinical Cancer Research

Completed

Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy

Leukemia

Switzerland
Washington University School of Medicine
Sunesis Pharmaceuticals

Completed

Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Daniel El Fassi
Technical University of Denmark

Completed

Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML (AZACTA)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Denmark

3

Subscribe